Cepheid has outlined its partnership with the Fleming Initiative, which it joined in 2024 as the first diagnostics company to do so, to strengthen the role of diagnostics against antimicrobial resistance.
The work includes TRACE-CPE, a real-world NHS study comparing rapid molecular screening for carbapenemase-producing Enterobacterales (about one hour) with culture-based screening (about 48 hours). It covers up to 16,000 tests at two London teaching hospitals and looks at effects on clinical decisions, patient flow, infection prevention and hospital transmission.
Source: Cepheid
Date: 11 November 2026
Original: https://www.cepheid.com/en-IE/insights/insight-hub/antimicrobial-stewardship/2026/11/cepheid-and-the-fleming-initiative.html
